PCRX241115C15000
- 2.40
- -0.35-12.73%
Pacira BioSciences Newsroom
Truist Financial Maintains Pacira BioSciences(PCRX.US) With Sell Rating
RBC Capital Maintains Sector Perform on Pacira BioSciences, Raises Price Target to $15
Pacira BioSciences Analyst Ratings
Jefferies Maintains Pacira BioSciences(PCRX.US) With Buy Rating, Cuts Target Price to $18
Jefferies & Co Adjusts Pacira BioSciences Price Target to $18 From $15, Maintains Buy Rating
Organon Downgraded, Amneal Upgraded as J.P. Morgan Reviews Specialty Pharma
Pacira BioSciences Analyst Ratings
Truist Financial Downgrades Pacira BioSciences(PCRX.US) to Sell Rating, Announces Target Price $8
Truist Securities Downgrades Pacira BioSciences to Sell From Buy, Adjusts Price Target to $8 From $30
Barclays Maintains Pacira BioSciences(PCRX.US) With Hold Rating, Maintains Target Price $25
Pacira Pharmaceuticals (PCRX) Gets a Hold From Barclays
Pacira Downgraded by J.P. Morgan, Piper, RBC, Raymond James
Needham Maintains Buy on Pacira BioSciences, Lowers Price Target to $22
Piper Sandler Downgrades Pacira BioSciences to Neutral From Overweight, Adjusts Price Target to $11 From $42
Pacira BioSciences Analyst Ratings
Barclays Maintains Pacira BioSciences(PCRX.US) With Hold Rating, Maintains Target Price $25
Pacira BioSciences Price Target Cut to $37.00/Share From $41.00 by Raymond James
Raymond James Maintains Outperform on Pacira BioSciences, Lowers Price Target to $37
Raymond James Maintains Pacira BioSciences(PCRX.US) With Buy Rating, Cuts Target Price to $37
A Quick Look at Today's Ratings for Pacira BioSciences(PCRX.US), With a Forecast Between $37 to $43